Compare · NVS vs VYNE
NVS vs VYNE
Side-by-side comparison of Novartis AG (NVS) and VYNE Therapeutics Inc. (VYNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and VYNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $295.78B, about 17406.2x VYNE ($17.0M).
- Over the past year, NVS is up 33.4% and VYNE is down 99.3% - NVS leads by 132.7 points.
- VYNE has been more active in the news (13 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 3 for VYNE).
- Company
- Novartis AG
- VYNE Therapeutics Inc.
- Price
- $154.98-0.83%
- $0.51-45.70%
- Market cap
- $295.78B
- $17.0M
- 1M return
- +1.17%
- -98.44%
- 1Y return
- +33.38%
- -99.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 1
- 13
- Recent ratings
- 25
- 3
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
Latest VYNE
- CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 23% to 74,918 units (SEC Form 4) (withholding obligation)
- CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 15,405 shares, decreasing direct ownership by 14% to 95,944 units (SEC Form 4) to cover taxes
- PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 79,391 shares, decreasing direct ownership by 19% to 347,174 units (SEC Form 4) (for tax liability)
- CHIEF LEGAL OFFICER AND GC Harsch Mutya covered exercise/tax liability with 22,516 shares, decreasing direct ownership by 19% to 95,918 units (SEC Form 4) to satisfy withholding tax
- VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
- VYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
- VYNE Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 425 filed by VYNE Therapeutics Inc.
- VYNE Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits